Conversion Right Triggered For LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 3, 2019-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject

GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to an Innovative Diagnostic Assay for Non-Alcoholic Steatohepatitis (NASH)

Multi-Biomarker Test Will Provide the Clinical Research Community with a Non-Invasive Tool to Identify and Monitor Patients with NASH and Significant Fibrosis LILLE, France & CAMBRIDGE, Mass. & BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 3, 2019-- LabCorp® (NYSE: LH), a leading global life sciences

LabCorp is Scheduled to Present at the 37th Annual J.P. Morgan Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 2, 2019-- LabCorp® (NYSE: LH) today announced it will participate at the 37th Annual J.P. Morgan Healthcare Conference . LabCorp’s presentation is scheduled for Tuesday, January 8, 2019 at 1:30 p.m. (PT) , followed by a question and answer session at 2:00

Covance Xcellerate® Wins Best Technological Development in Clinical Trials (Clinical Sponsor-Focused) at 14th Annual Scrip Awards

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 7, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, today announced that its Covance Drug Development (Covance) business was awarded Best Technological Development in Clinical Trials (Clinical Sponsor-Focused) at the 14th Annual Scrip

Covance Honored with Frost & Sullivan Asia Pacific Award for Fifth Consecutive Year

Awarded CRO 2018 Customer Value Leadership Award BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 6, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, today announced that its Covance Drug Development business (Covance) has been awarded the 2018 Frost & Sullivan Asia Pacific CRO Customer

LabCorp Updates Full-Year 2018 Guidance

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 30, 2018-- LabCorp® (or the Company) (NYSE: LH) today updated its full-year 2018 guidance based on current expectations. In the following guidance, all comparisons to financial results in 2017 have been restated as if the Company had adopted the FASB-issued

Be The Match Partners with LabCorp to Help Grow Donor Registry

Enhanced partnership will support equal transplant outcomes for blood cancer and blood disorder patients Be The Match ® and LabCorp have enhanced their long-standing partnership through the launch of an information and enrollment campaign at LabCorp patient service centers with a goal to add a